Public Sector Pension Investment Board Has $6.86 Million Position in Artivion, Inc. $AORT

Public Sector Pension Investment Board lifted its holdings in Artivion, Inc. (NYSE:AORT) by 23.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 161,970 shares of the company’s stock after acquiring an additional 30,989 shares during the period. Public Sector Pension Investment Board owned approximately 0.34% of Artivion worth $6,858,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Invesco Ltd. grew its stake in Artivion by 40.8% during the second quarter. Invesco Ltd. now owns 481,026 shares of the company’s stock worth $14,960,000 after purchasing an additional 139,370 shares during the period. Osterweis Capital Management Inc. bought a new stake in shares of Artivion in the 2nd quarter valued at $3,750,000. Bank of America Corp DE lifted its position in shares of Artivion by 22.8% during the 2nd quarter. Bank of America Corp DE now owns 645,070 shares of the company’s stock valued at $20,062,000 after acquiring an additional 119,634 shares during the period. Balyasny Asset Management L.P. bought a new position in Artivion during the second quarter worth $2,582,000. Finally, Bridger Management LLC grew its holdings in Artivion by 106.2% in the second quarter. Bridger Management LLC now owns 132,588 shares of the company’s stock worth $4,123,000 after purchasing an additional 68,288 shares during the period. Institutional investors own 86.37% of the company’s stock.

Analyst Ratings Changes

AORT has been the topic of a number of research analyst reports. Citizens Jmp increased their price objective on shares of Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a research report on Friday, November 7th. Needham & Company LLC reiterated a “buy” rating and issued a $58.00 price target on shares of Artivion in a report on Monday, February 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Artivion in a research note on Wednesday, January 21st. Canaccord Genuity Group lowered their target price on Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a research report on Friday, February 13th. Finally, Wall Street Zen cut Artivion from a “buy” rating to a “hold” rating in a report on Saturday. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $48.97.

Artivion Stock Performance

Shares of Artivion stock opened at $36.50 on Wednesday. Artivion, Inc. has a 52 week low of $21.97 and a 52 week high of $48.25. The company has a quick ratio of 2.62, a current ratio of 3.53 and a debt-to-equity ratio of 0.49. The business has a 50 day moving average price of $43.30 and a 200-day moving average price of $43.02. The company has a market cap of $1.73 billion, a PE ratio of 182.51 and a beta of 1.59.

Artivion (NYSE:AORT) last announced its quarterly earnings results on Thursday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.03. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The business had revenue of $118.30 million during the quarter, compared to the consensus estimate of $116.42 million. The business’s revenue for the quarter was up 19.2% compared to the same quarter last year. Equities analysts anticipate that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Insider Activity

In other news, CAO Amy Horton sold 4,572 shares of the company’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $44.42, for a total value of $203,088.24. Following the completion of the transaction, the chief accounting officer directly owned 130,058 shares of the company’s stock, valued at $5,777,176.36. This represents a 3.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO James P. Mackin sold 30,921 shares of the stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $45.56, for a total value of $1,408,760.76. Following the sale, the chief executive officer directly owned 800,993 shares of the company’s stock, valued at $36,493,241.08. The trade was a 3.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 105,460 shares of company stock valued at $4,751,927 over the last ninety days. Company insiders own 8.10% of the company’s stock.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.